Seeking Alpha
 

Stryker Corporation (SYK)

- NYSE
  • Jul. 19, 2013, 3:08 PM
    Shares of Stryker (SYK +0.3%) are fractionally higher in afternoon trading after starting the day in negative territory following Thursday's Q2 report which saw the company cut its full year EPS guidance to $4.20-4.26 from $4.25-4.40 (consensus is $4.29). Barron's highlights a Canaccord note in which analysts reiterate a Buy recommendation based on "above market" growth, market share gains in hip and trauma/extremities, and new leadership. Wunderlich downgraded the shares today to Hold but the firm's price target is still above current levels. (For more: CC transcript)
    | Comment!
  • Jul. 18, 2013, 4:21 PM
    Stryker (SYK): Q2 EPS of $1.00 misses by $0.03. Revenue of $2.21B (+5% Y/Y) beats by $0.02B. Shares -1.4% AH. (PR)
    | Comment!
  • Jul. 18, 2013, 12:10 AM
    Notable earnings after Thursday’s close: GOOG,MSFT, AMD, CMG, ISRG, SWKS, SYK, COF, BGS , RMBS, PBCT, CBST, ACTG, ATHN, CPHD,ALGN, CE, WAL, CYT
    | Comment!
  • Jul. 17, 2013, 5:35 PM
    Notable earnings after Thursday’s close: GOOG,MSFT, AMD, CMG, ISRG, SWKS, SYK, COF, BGS , RMBS, PBCT, CBST, ACTG, ATHN, CPHD,ALGN, CE, WAL, CYT
    | Comment!
  • May 17, 2013, 7:18 AM
    Stryker (SYK) is downgraded to Reduce at SunTrust as a bank survey sows ACO's, CMS bundling, and readmission will negatively impact hips and knees pricing.
    | Comment!
  • Apr. 29, 2013, 3:59 PM
    Vascular specialists at Carolinas HealthCare System in Charlotte, North Carolina, and the Cleveland Clinic in Ohio perform the initial implants of a novel stent graft system from Medtronic (MDT +1%) as part of an FDA initiative designed to encourage more early-stage clinical research on new medical devices in the U.S. The implants are among the first to be performed under the agency's early feasibility pilot program, which includes a total of nine medical devices from different companies.
    | Comment!
  • Apr. 24, 2013, 4:32 PM
    More on Stryker (SYK): Q1 beats on its EPS but comes up short on revenue. Net earnings fell 13% Y/Y as product-recall-related charges offset better sales growth. Reconstructive-products business +2.8%, hip products sales -0.8% and knee products -1%. In its neurotechnology and spine segment sales were up 5.7%, despite a 1.8% drop in spine-product sales.
    | Comment!
  • Apr. 24, 2013, 4:14 PM
    Stryker (SYK): EPS of $1.03 beats by $0.02. Revenue of $2.19B (+1% Y/Y) misses by $20M. (PR). Tune in to its conference call here: (Webcast)
    | Comment!
  • Apr. 24, 2013, 12:10 AM
    Notable earnings after Wednesday’s close: AFL, AIZ, AKAM, ANGI, ARII, ARRS, ASGN, AVG, BAS, BDN, CAKE, CCI, CDNS, CLF, CLGX, CMO, CMRE, COG, CROX, CTXS, DRE, DRWI, EFX, EQIX, FFIV, FIO, FLS, GGG, INFN, ISIL, ITMN, JAH, KEX, LOGI, LPS, LRCX, LSI, MLNX, NEU, NOW, OIS, ORLY, OTEX, PDH, PMTC, QCOM, RJF, RYL, SCI, SKX, SRCL, SUSQ, SYK, TAL, TER, TEX, TQNT, TSCO, TWI, VAR, WCN, WDC, WLL, XLNX, XNPT, ZNGA
    | 1 Comment
  • Apr. 23, 2013, 5:35 PM
    Notable earnings after Wednesday’s close: AFL, AIZ, AKAM, ANGI, ARII, ARRS, ASGN, AVG, BAS, BDN, CAKE, CCI, CDNS, CLF, CLGX, CMO, CMRE, COG, CROX, CTXS, DRE, DRWI, EFX, EQIX, FFIV, FIO, FLS, GGG, INFN, ISIL, ITMN, JAH, KEX, LOGI, LPS, LRCX, LSI, MLNX, NEU, NOW, OIS, ORLY, OTEX, PDH, PMTC, QCOM, RJF, RYL, SCI, SKX, SRCL, SUSQ, SYK, TAL, TER, TEX, TQNT, TSCO, TWI, VAR, WCN, WDC, WLL, XLNX, XNPT, ZNGA
    | Comment!
  • Apr. 10, 2013, 4:03 PM
    Stryker (SYK +0.6%) says that its orthopaedic division has received notice that the FDA has reviewed the voluntary recall of its ShapeMatch Cutting Guides and will rate it as a Class I recall. According to the agency's outline, a Class 1 recall describes a situation in which there is a reasonable probability that the product will cause "serious adverse health consequences." SYK voluntarily recalled the devices in January, saying some may have been improperly manufactured.
    | Comment!
  • Apr. 8, 2013, 9:31 AM
    Stryker (SYK) names William Jellison as CFO to replace Dean Bergy, who has been serving in the job on an interim basis. Jellison comes from dental equipment maker Dentsply (XRAY), where he was CFO. Jellison's appointment is effective from April 22. Dentsply appoints company President and COO Chris Clark to replace Jellison. (PR)
    | Comment!
  • Mar. 21, 2013, 11:42 AM
    Stryker (SYK -0.9%) slips after pricing an offering to sell $600M in unsecured notes due 2018 and $400M of notes due 2043. The company plans to use the proceeds from the offering for working capital and other general corporate purposes, including acquisitions, stock repurchases and other business opportunities.
    | Comment!
  • Mar. 12, 2013, 8:46 AM
    Stryker's (SYK -0.5%) Instruments division has received a warning letter from the FDA following an inspection at the company's facility in Portage, Michigan in November, when the agency had concerns about the plant's quality systems. The letter also cites Stryker for not notifying the FDA about a product recall, and for marketing devices, including the Neptune Waste Management System, without 510(k) clearance. (PR)
    | Comment!
  • Jan. 23, 2013, 4:22 PM
    More on Stryker (SYK): Q4 beats on both EPS and revenue estimates on a 4.2% Y/Y increase in sales. Net profit fell 33% Y/Y on hefty charges related to a product recall, while sales continued to strengthen. Neuro-technology and Spine net sales increased 9.7% Y/Y, with its reconstructive segment growing by 6.7% over the same period.
    | Comment!
  • Jan. 23, 2013, 4:07 PM
    Stryker (SYK): Q4 EPS of $1.14 beats by $0.01. Revenue of $2.34B (+4.2% Y/Y) beats by $70M. (PR)
    | Comment!
Visit Seeking Alpha's
SYK vs. ETF Alternatives
Company Description
Stryker Corporation is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.